Holen Sie sich die Stockscreener-App
26.34
4.74%
-1.31
Schlusskurs vom Vortag:
$27.65
Offen:
$27.65
24-Stunden-Volumen:
1.15M
Relative Volume:
0.84
Marktkapitalisierung:
$3.31B
Einnahmen:
$-665.00K
Nettoeinkommen (Verlust:
$-150.11M
KGV:
-17.48
EPS:
-1.5071
Netto-Cashflow:
$-124.53M
1W Leistung:
-6.40%
1M Leistung:
-19.28%
6M Leistung:
+48.56%
1J Leistung:
+73.63%
1-Tages-Spanne:
$26.20
$27.65
1-Wochen-Bereich:
$26.20
$28.49
52-Wochen-Spanne:
$10.83
$41.14
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Telefon
617-682-0917
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
26.34 | 3.31B | -665.00K | -150.11M | -124.53M | -1.5071 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-03 | Eingeleitet | Stifel | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Guggenheim | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-05-30 | Eingeleitet | TD Cowen | Buy |
| 2025-04-07 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-11-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-03-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-01-05 | Eingeleitet | BofA Securities | Buy |
| 2022-05-25 | Eingeleitet | Citigroup | Buy |
| 2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
A director proposes selling 100,000 shares of Amylyx Pharmaceuticals (AMLX). - Stock Titan
Amylyx Pharmaceuticals, Inc. (AMLX) Latest Stock News & Headlines - Yahoo! Finance Canada
Certain Restricted Stock Unit of Amylyx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-OCT-2026. - www.marketscreener.com
Certain Common Stock of Amylyx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-OCT-2026. - marketscreener.com
Amylyx Pharmaceuticals, Inc. (AMLX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum - Business Wire
Amylyx (NASDAQ: AMLX) co-CEO sells shares to cover taxes - Stock Titan
Automatic tax sale by Amylyx (NASDAQ: AMLX) CFO - Stock Titan
Automatic tax-share sale by Amylyx (AMLX) legal chief - Stock Titan
Amylyx Pharmaceuticals (AMLX) co-CEO sells shares to cover tax bill - Stock Titan
Amylyx (AMLX) CMO auto-sells 10,028 shares for taxes - Stock Titan
Amylyx Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Automatic stock sale for taxes ahead at Amylyx Pharmaceuticals (AMLX) - Stock Titan
Amylyx (NASDAQ: AMLX) insider schedules automatic 60K-share sale - Stock Titan
Amylyx (NASDAQ: AMLX) officer lines up tax-driven share sale - Stock Titan
Amylyx (AMLX) insider schedules automatic tax share sale - Stock Titan
Automatic Amylyx (AMLX) stock sale set to cover taxes - Stock Titan
After two decades at Alkermes, a biotech CFO joins Tortugas’ board - Stock Titan
Amylyx Pharmaceuticals Inks Avexitide Supply Deals With Bachem and Polypeptide; $30 Million Upfront to Reserve Capacity - TradingView
Amylyx Pharmaceuticals | 8-K: Current report - Moomoo
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference - Business Wire
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference - Yahoo Finance
The Manufacturers Life Insurance Company Makes New $679,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals (AMLX) director exercises 50K stock options - Stock Titan
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? - Yahoo Finance
Amylyx Pharmaceuticals (AMLX) Is Down 10.1% After Strong Phase 3 Avexitide Data And $500M Equity Raise – Has The Bull Case Changed? - webull.com
Should Eli Lilly Investors Be Worried About a Threat From Amylyx? - Yahoo Finance
Oracle Stock Stands Out Among Healthy High Growth Potential Picks - sahmcapital.com
Oracle Stock And Palantir Shares Stand Out For High Growth Investors - Sahm
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Guggenheim raises Amylyx stock price target on financing, trial data By Investing.com - Investing.com Australia
Guggenheim raises Amylyx stock price target on financing, trial data - investing.com
Amylyx Pharmaceuticals (NasdaqGS:AMLX) Stock Forecast & Analyst Predictions - Simply Wall Street
Oracle Stock And Two Other Growth Names With Stronger Balance Sheet Appeal - sahmcapital.com
Rocket Lab Stock Leads 3 High Growth Picks With Fresh Earnings Upside - Sahm
LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week - Yahoo Finance
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company? - Yahoo Finance
MercadoLibre Stock And 2 High Growth Picks With Strong Balance Sheets - Sahm
Amylyx Pharmaceuticals (AMLX) co-CEO nets 60K performance shares - Stock Titan
Amylyx (NASDAQ: AMLX) CMO’s stock award lifts stake to 288,092 shares - Stock Titan
Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide - TipRanks
Amylyx Pharmaceuticals Announces $471.7 Million Public Stock Offering Priced at $35.50 Per Share - Kalkine Media
Amylyx Pharmaceuticals Prices 14.09M-Share Public Offering at $35.50; Nets ~$472M - TradingView
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock - BioSpace
Amylyx Pharmaceuticals Jumps to Fresh Three-Year High as Avexitide Phase 3 Results Bolster Commercial Path - Vinanet
HC Wainwright Has Strong Forecast for AMLX FY2028 Earnings - MarketBeat
39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by GSA Capital Partners LLP - MarketBeat
Amylyx Pharmaceuticals (AMLX) CEO granted 60K shares - Stock Titan
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amylyx Pharmaceuticals Inc-Aktie (AMLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GEORGE MILNE | Director |
Oct 05 '26 |
Proposed Sale |
27.79 |
100,000 |
2,779,000 |
0 |
| Klee Justin B. | Co-Chief Executive Officer |
Sep 10 '26 |
Sale |
32.18 |
30,464 |
980,263 |
3,613,056 |
| Cohen Joshua B | Co-Chief Executive Officer |
Sep 10 '26 |
Sale |
32.19 |
30,464 |
980,504 |
3,613,123 |
| FRATES JAMES M | Chief Financial Officer |
Sep 10 '26 |
Sale |
32.36 |
10,810 |
349,821 |
233,625 |
| Klee Justin B. | Officer |
Sep 10 '26 |
Proposed Sale |
32.18 |
30,464 |
980,264 |
0 |
| Frates James M | Officer |
Sep 10 '26 |
Proposed Sale |
32.36 |
10,810 |
349,821 |
0 |
| Bedrosian Camille L | Officer |
Sep 10 '26 |
Proposed Sale |
32.40 |
10,028 |
324,868 |
0 |
| Cohen Joshua B | Officer |
Sep 10 '26 |
Proposed Sale |
32.19 |
30,464 |
980,504 |
0 |
| Mazzariello Gina | Officer |
Sep 10 '26 |
Proposed Sale |
32.46 |
9,536 |
309,506 |
0 |
| Mazzariello Gina | Chief Legal Officer |
Sep 10 '26 |
Sale |
32.46 |
9,536 |
309,506 |
190,838 |
1.24%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):